{
    "root": "55b18d8f-40e0-48ba-baf1-79a0d1bb2ee2",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Ezetimibe",
    "value": "20250301",
    "ingredients": [
        {
            "name": "EZETIMIBE",
            "code": "EOR26LQQ24"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        }
    ],
    "indications": "ezetimibe tablets indicated : \u2022 combination statin , alone additional low-density lipoprotein cholesterol ( ldl-c ) lowering therapy possible , adjunct diet reduce elevated ldl-c adults primary hyperlipidemia , including heterozygous familial hypercholesterolemia ( hefh ) . \u2022 combination statin adjunct diet reduce elevated ldl-c pediatric patients 10 years age older hefh . \u2022 combination fenofibrate adjunct diet reduce elevated ldl-c adults mixed hyperlipidemia . \u2022 combination statin , ldl-c lowering therapies , reduce elevated ldl-c levels adults pediatric patients 10 years age older homozygous familial hypercholesterolemia ( hofh ) . \u2022 adjunct diet reduction elevated sitosterol campesterol levels adults pediatric patients 9 years age older homozygous familial sitosterolemia . ezetimibe tablet used combination statin , fenofibrate , ldl-c lowering therapies , refer prescribing information products information safe effective .",
    "contraindications": "\u2022the recommended dose ezetimibe tablet 10 mg orally daily , administered without food . \u2022 dose missed , take missed dose soon possible . double next dose . \u2022 assess ldl-c clinically appropriate , early 4 weeks initiating ezetimibe tablets . \u2022 administer ezetimibe tablets least 2 hours 4 hours bile acid sequestrant [ seedrug ( 7 ) ] .",
    "warningsAndPrecautions": "ezetimibe tablets , usp 10 mg , white off-white , capsule-shaped , flat , beveled edged tablets engraved \u2018 g80 \u2019 one side plain side . supplied follows : bottles 30 , ndc 82804-211-30 store ezetimibe tablets , usp 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] . protect moisture .",
    "adverseReactions": "ezetimibe tablets contraindicated patients known hypersensitivity ezetimibe excipients ezetimibe tablets . hypersensitivity including anaphylaxis , angioedema , rash , urticaria reported [ ( 6.2 ) ] . used combination statin , fenofibrate , ldl-c lowering therapy , ezetimibe tablets contraindicated patients statin , fenofibrate , ldl-c lowering therapy contraindicated . refer prescribing information products list [ ( 5.1 ) ] .",
    "indications_original": "Ezetimibe tablets are indicated:\n                  \n                  \n                     \n                        \u2022\n                        \n                           In combination with a statin, or alone when additional low-density lipoprotein cholesterol (LDL-C) lowering therapy is not possible, as an adjunct to diet to reduce elevated LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH). \n                        \n                     \n                     \n                        \u2022\n                        In combination with a statin as an adjunct to diet to reduce elevated LDL-C in pediatric patients 10 years of age and older with HeFH. \n                     \n                     \n                        \u2022\n                        In combination with fenofibrate as an adjunct to diet to reduce elevated LDL-C in adults with mixed hyperlipidemia. \n                     \n                     \n                        \u2022\n                        In combination with a statin, and other LDL-C lowering therapies, to reduce elevated LDL-C levels in adults and in pediatric patients 10 years of age and older with homozygous familial hypercholesterolemia (HoFH). \n                     \n                     \n                        \u2022\n                        As an adjunct to diet for the reduction of elevated sitosterol and campesterol levels in adults and in pediatric patients 9 years of age and older with homozygous familial sitosterolemia. \n                     \n                  \n                  \n                     When ezetimibe tablet is used in combination with a statin, fenofibrate, or other LDL-C lowering therapies, refer to the Prescribing Information of these products for information on the safe and effective use.",
    "contraindications_original": "\u2022The recommended dose of ezetimibe tablet is 10 mg orally once daily, administered with or without food. \n                     \n                        \u2022\n                        If as dose is missed, take the missed dose as soon as possible. Do not double the next dose. \n                     \n                     \n                        \u2022\n                        Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating ezetimibe tablets. \n                     \n                     \n                        \u2022\n                        Administer ezetimibe tablets at least 2 hours before or 4 hours after administration of a bile acid sequestrant [seeDrug Interactions (\n                        \n                        \n                           7\n                           )].",
    "warningsAndPrecautions_original": "Ezetimibe Tablets, USP 10 mg, are white to off-white, capsule-shaped, flat, beveled edged tablets engraved with \u2018G80\u2019 on one side and plain on the other side. They are supplied as follows: \n                  Bottles of 30, NDC 82804-211-30 \n                  Store Ezetimibe Tablets, USP at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted to 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F) [see USP Controlled Room Temperature]. Protect from moisture.",
    "adverseReactions_original": "Ezetimibe tablets are contraindicated in patients with a known hypersensitivity to ezetimibe or any of the excipients in ezetimibe tablets. Hypersensitivity reactions including anaphylaxis, angioedema, rash, and urticaria have been reported [see Adverse Reactions (6.2)].\n                     \n                        \u00a0\n                        When used in combination with a statin, fenofibrate, or other LDL-C lowering therapy, ezetimibe tablets are contraindicated in patients for whom a statin, fenofibrate, or other LDL-C lowering therapy are contraindicated. Refer to the Prescribing Information of these products for a list of their contraindications [see Warnings and Precautions (\n                        \n                        \n                           5.1\n                           )]."
}